Quantedge Capital Sells Entire Stake in Supernus Pharmaceuticals Amid Strong Stock Performance
Quantedge Capital sold its entire stake of 89,600 shares in Supernus Pharmaceuticals during Q1 2026 for an estimated $4.56 million. The position had previously accounted for up to 2.5% of the fund's AUM and was part of a broader portfolio adjustment.
Tickers: $SUPN
Topics: 13F report Quantedge Capital SEC filing Supernus Pharmaceuticals